Making Invisible, Undiagnosed Rare Disease Patients Visible to Healthcare.

RDDT combines proprietary rare disease analytics, compliant biopharmaceutical sponsorship, and independent clinical governance to create new opportunities for physician-directed rare disease evaluation within healthcare organizations.

Contact Us

RDDT provides U.S. healthcare organizations with Rare Disease Patient Analytic Services, which combine compliant patient-first funding, proprietary analytics, independent clinical review, and patient-consented, physician-directed evaluation to create new, sustainable revenue for healthcare organizations while advancing earlier recognition and diagnosis of previously unsuspected rare disease patients for whom potentially life-saving FDA-approved therapies already exist, within their existing healthcare systems.

Patients

Patient-First

As an independent, neutral intermediary, RDDT places patients at the center of its operating model. Our first responsibility is to expand opportunities for earlier recognition, diagnosis, and appropriate care, while protecting patient privacy, preserving physician independence, and respecting patient choice.

Learn More
Healthcare Organizations

Physician-Connected

RDDT analyzes only authorized, de-identified clinical information, while the healthcare organization retains patient identity and control of subsequent physician and patient engagement.  Healthcare organizations participate through institutionally governed agreements.

Learn More
BioPharma Sponsors

Independent Clinical Evaluation

Support authorized, population-level rare disease analytics within participating healthcare organizations, under independent institutional governance and physician authority, for the benefit of patients awaiting diagnosis.

Learn More

For the Benefit of Patients Awaiting a Rare Disease Diagnosis

The Missing Link

Most Rare Disease Patients Are Already in the Healthcare System

They have seen physicians. Their symptoms are documented. Their records exist. Yet the connection between their clinical presentation and a rare disease diagnosis has never been made.

RDDT's platform analyzes existing clinical evidence under healthcare organization governance and physician authority, surfacing patients whose rare diseases may have gone unrecognized for years or decades.

This is not merely a research initiative. It is an operational clinical pathway designed to create actionable opportunities.

The data already exists. The patients are already there. RDDT helps connect the evidence to the physicians who can pursue a diagnosis.

The RDDT Difference

An Architecture Built to Change Rare Disease Healthcare

Not simply better technology. A fundamentally different operating model.

Rare disease patients have remained invisible not because healthcare lacks clinical information, but because it has lacked a systematic, economically sustainable way to surface previously unsuspected patients and support their independent clinical evaluation. RDDT changes that equation.

01

Clinical Intelligence Beyond Claims Data

RDDT analyzes longitudinal clinical evidence within participating healthcare organizations, surfacing high-confidence clinical patterns and previously unsuspected patients that may not be apparent from claims data alone, and is not actionable from claims data alone.

02

Economics That Create Capacity

Our compliant, outcome-independent fair-market-value framework compensates healthcare organizations for authorized population searches and defined Clinical Evaluation & Reconciliation Services, creating the sustainable organizational capacity to pursue previously overlooked patients.

03

Built for Permission and Clinical Independence

Healthcare organizations control patient identity, clinical governance, and physician engagement. Independent clinical experts evaluate suspect cohorts, while physicians retain exclusive authority over evaluation, diagnosis, and treatment. RDDT operates as a neutral intermediary.

04

National Reach Without Network Boundaries

RDDT's repeatable analytical infrastructure and institutional governance framework enable expansion across healthcare organizations nationwide, without dependence on a fixed network, a single EHR platform, or a particular geography.

A sustainable healthcare capability that brings previously unrecognized rare disease patients to the attention of the physicians responsible for their care.

Provider-Connected. Independent Clinical Evaluation.

A Model Built Around the Patient & Physician Relationship

RDDT operates through a physician-connected model that preserves the integrity of existing clinical relationships while creating new opportunities to surface patients awaiting diagnosis.

RDDT operates within participating healthcare organizations' established privacy and data-governance frameworks, preserving patient choice, physician independence, and the integrity of existing clinical relationships. Every insight is connected back to a treating physician. Every finding is returned for independent clinical evaluation — not simply flagged as statistically interesting — with the patient as the primary intended beneficiary.

01

Powerfully Patient Centric

02

Expanding Healthcare Reach Through Intelligence and Economics

03

Consented Engagement & Physician-Led Care

04

Measureable, Reportable & Accountable  Outcomes

From Unrecognized Clinical Evidence to Independent Physician Evaluation, Guided by Clinical Governance.

"In the United States, hundreds of thousands of rare disease patients remain undiagnosed despite the existence of FDA-approved, disease-modifying therapies for their condition. Their conditions may continue to progress, sometimes irreversibly. We intend to do something about that problem."

David Silas Connor

Founder & Chief Executive Officer

Rare Disease Data Trust

The Next Chapter in Rare Disease Medicine

The Science Has Advanced. Now We Must Reach the Patients.

The Orphan Drug Act helped transform rare disease medicine. Scientific advances have created treatment possibilities that were once unimaginable. Yet patients whose diseases remain unrecognized cannot fully benefit from those breakthroughs.

RDDT was founded to address that unfinished challenge by making existing clinical evidence more visible, preserving independent physician judgment, and building the economic capacity to act.

The next great advancement in rare disease medicine is not only discovering new treatments. It is ensuring that patients have the opportunity to benefit from the treatments we already have.

Contact Us